Octreotide sustained release - Midatech

Drug Profile

Octreotide sustained release - Midatech

Alternative Names: MTD-201; Q-Octreotide

Latest Information Update: 14 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Midatech
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acromegaly; Malignant carcinoid syndrome

Most Recent Events

  • 14 Jul 2016 Chemical structure information added
  • 18 May 2016 Midatech plans to file an IND for octreotide sustained release with the US FDA and initiate human bioequivalence studies in first half of 2017
  • 11 May 2016 Octreotide sustained release licensed to Centurion Pharma in Turkey
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top